A panel of BRAF inhibitors (BRAFi-s) (vemurafenib, dabrafenib, encorafenib, etc.)and a series of MEK inhibitors (MEKi-s) (cobimetinib, trametinib, binimetinib, etc.)have revolutionized the treatment of melanoma patients [6]. This evidence concerns the gene MAP2K7 and melanoma.